Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin J Bergman

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Rheumatology and Therapy|November 5, 2022
Clinical and Economic Benefit of Achieving Disease Control in Psoriatic Arthritis and Ankylosing Spondylitis: A Retrospective Analysis from the OM1 RegistryMartin J Bergman, Patrick Zueger, Jayeshkumar Patel, et al.
Clinical Rheumatology|April 16, 2018
Evaluation of disease activity in patients with rheumatoid arthritis treated with tofacitinib by RAPID3: post hoc analyses from two phase 3 trialsVibeke Strand, Eun Bong Lee, Yusuf Yazici, et al.
Arthritis Care & Research|March 2, 2010
RAPID3 (Routine Assessment of Patient Index Data) on an MDHAQ (Multidimensional Health Assessment Questionnaire): agreement with DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) activity categories, scored in five versus more than ninety secondsTheodore Pincus, Christopher J Swearingen, Martin J Bergman, et al.
Seminars in Arthritis and Rheumatism|May 24, 2012
Proceedings of the 2012 Rheumatology Winter Clinical SymposiaArthur Kavanaugh, George Martin, John J Cush, et al.
The Journal of Rheumatology|November 18, 2009
Is fatigue an inflammatory variable in rheumatoid arthritis (RA)? Analyses of fatigue in RA, osteoarthritis, and fibromyalgiaMartin J Bergman, Shadi H Shahouri, Shadi S Shahouri, et al.
The Lancet. Rheumatology|January 30, 2024
The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trialVibeke Strand, Gurjit S Kaeley, Martin J Bergman, et al.
Arthritis Care & Research|November 12, 2019
2019 Update of the American College of Rheumatology Recommended Rheumatoid Arthritis Disease Activity MeasuresBryant R England, Benedict K Tiong, Martin J Bergman, et al.
Arthritis Care & Research|February 1, 2020
ReplyBryant R England, Ted R Mikuls, James R O'Dell, et al.
Rheumatology International|June 1, 2017
Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and CanadaLaure Weijers, Christoph Baerwald, Francesco S Mennini, et al.
Arthritis Care & Research|July 9, 2016
Methods for Developing the American College of Rheumatology's Electronic Clinical Quality MeasuresJinoos Yazdany, Rachel Myslinski, Amy Miller, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Rheumatology and Therapy|November 5, 2022
Clinical and Economic Benefit of Achieving Disease Control in Psoriatic Arthritis and Ankylosing Spondylitis: A Retrospective Analysis from the OM1 RegistryMartin J Bergman, Patrick Zueger, Jayeshkumar Patel, et al.
Clinical Rheumatology|April 16, 2018
Evaluation of disease activity in patients with rheumatoid arthritis treated with tofacitinib by RAPID3: post hoc analyses from two phase 3 trialsVibeke Strand, Eun Bong Lee, Yusuf Yazici, et al.
Arthritis Care & Research|March 2, 2010
RAPID3 (Routine Assessment of Patient Index Data) on an MDHAQ (Multidimensional Health Assessment Questionnaire): agreement with DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) activity categories, scored in five versus more than ninety secondsTheodore Pincus, Christopher J Swearingen, Martin J Bergman, et al.
Seminars in Arthritis and Rheumatism|May 24, 2012
Proceedings of the 2012 Rheumatology Winter Clinical SymposiaArthur Kavanaugh, George Martin, John J Cush, et al.
The Journal of Rheumatology|November 18, 2009
Is fatigue an inflammatory variable in rheumatoid arthritis (RA)? Analyses of fatigue in RA, osteoarthritis, and fibromyalgiaMartin J Bergman, Shadi H Shahouri, Shadi S Shahouri, et al.
The Lancet. Rheumatology|January 30, 2024
The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trialVibeke Strand, Gurjit S Kaeley, Martin J Bergman, et al.
Arthritis Care & Research|November 12, 2019
2019 Update of the American College of Rheumatology Recommended Rheumatoid Arthritis Disease Activity MeasuresBryant R England, Benedict K Tiong, Martin J Bergman, et al.
Arthritis Care & Research|February 1, 2020
ReplyBryant R England, Ted R Mikuls, James R O'Dell, et al.
Rheumatology International|June 1, 2017
Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and CanadaLaure Weijers, Christoph Baerwald, Francesco S Mennini, et al.
Arthritis Care & Research|July 9, 2016
Methods for Developing the American College of Rheumatology's Electronic Clinical Quality MeasuresJinoos Yazdany, Rachel Myslinski, Amy Miller, et al.
Pageof 4